Endo International (ENDP) Stock Heads Up On FDA Approval

Endo International ENDP Stock News

Endo International PLC (NASDAQ: ENDP) is making a run for the top in the market this morning, and for good reason. The company announced that the FDA has approved a new treatment, the first in its class. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

ENDP Stock Heads Up On FDA Approval

In the press release, Endo International said that the United States Food and Drug Administration, or FDA, has approved QWO. The treatment was designed and approved for the treatment of moderate to severe cellulite in the buttocks of adult women.

Importantly, QWO is the first and only FDA-approved injectible treatment for cellulite. Qwo was designed to release fibrous septae enzymatically by specifically targeting Types 1 and 3 collagen. In clinical studies, this process was shown to result in the smoothing of skin and an improved appearance of cellulite.

ENDP said that it is expecting for QWO to be available throughout the United States starting in the Spring of 2021. For updates on product availability, interested consumers and physicians can visit www.QWO.com.

In a statement, Blaise Coleman, President and CEO at ENDP, had the following to offer:

Today’s FDA approval of QWO is a key achievement in the continued execution of Endo’s long-term strategy, especially as it relates to building our portfolio and capabilities for the future. As Endo embarks on an exciting new journey into medical aesthetics, we look forward to bringing this innovative treatment to market through our Endo Aesthetics organization.

The above statement was followed up by Matthew Davis, M.D., R.Ph., SVP and CMO at ENDP. Here’s what he had to say:

Endo recognized a significant unmet need for an effective and non-invasive injectable treatment for cellulite, which led us to conduct the largest clinical trials in the history of cellulite investigation in the United States. Supported by rigorous research, testing and development processes, we are proud to have received FDA approval of the first injectable treatment for cellulite in the buttocks and we look forward to delivering QWO to the aesthetics community and their adult female patients.

This Is Very Exciting News

The news released by Endo Inernational this morning is overwhelmingly positive for multiple reasons. First and foremost, this is the first injectible treatment for cellulite to ever hit the market.

That’s great news because that means there there is no direct competition. While there are creams and rubs that are believed to help the appearance of the condition, this will be the strongest options for patients looking to treat cellulite in the buttocks.

It’s also worth mentioning that cellulite treatment was a $1.35 billion market last year, and that market is only expected to grow. With ENDP owning the first approved injection, there’s a strong chance that the company will take a large portion of the market once this product is released next spring.

The bottom line here is that QWO has the potential to become a blockbuster option, making ENDP stock one that’s hard to ignore.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.